Characteristics and Outcomes of People With Gout Hospitalized Due to COVID-19: Data From the COVID-19 Global Rheumatology Alliance Physician-Reported Registry

Kanon Jatuworapruk, Anna Montgomery, Milena Gianfrancesco, Richard Conway, Laura Durcan, Elizabeth R. Graef, Aruni Jayatilleke, Helen Keen, Adam Kilian, Kristen Young, Loreto Carmona, Adriana Karina Cogo, Alí Duarte-García, Laure Gossec, Rebecca Hasseli, Kimme L. Hyrich, Vincent Langlois, Saskia Lawson-Tovey, Armando Malcata, Elsa F. MateusMartin Schafer, Carlo Alberto Scirè, Valgerdur Sigurdardottir, Jeffrey A. Sparks, Anja Strangfeld, Ricardo M. Xavier, Suleman Bhana, Monique Gore-Massy, Jonathan Hausmann, Jean W. Liew, Emily Sirotich, Paul Sufka, Zach Wallace, Pedro M. Machado, Jinoos Yazdany, Rebecca Grainger, Philip C. Robinson

Research output: Contribution to journalArticlepeer-review

4 Citations (Web of Science)


Objective: To describe people with gout who were diagnosed with coronavirus disease 2019 (COVID-19) and hospitalized and to characterize their outcomes. Methods: Data on patients with gout hospitalized for COVID-19 between March 12, 2020, and October 25, 2021, were extracted from the COVID-19 Global Rheumatology Alliance registry. Descriptive statistics were used to describe the demographics, comorbidities, medication exposures, and COVID-19 outcomes including oxygenation or ventilation support and death. Results: One hundred sixty-three patients with gout who developed COVID-19 and were hospitalized were included. The mean age was 63 years, and 85% were male. The majority of the group lived in the Western Pacific Region (35%) and North America (18%). Nearly half (46%) had two or more comorbidities, with hypertension (56%), cardiovascular disease (28%), diabetes mellitus (26%), chronic kidney disease (25%), and obesity (23%) being the most common. Glucocorticoids and colchicine were used pre-COVID-19 in 11% and 12% of the cohort, respectively. Over two thirds (68%) of the cohort required supplemental oxygen or ventilatory support during hospitalization. COVID-19-related death was reported in 16% of the overall cohort, with 73% of deaths documented in people with two or more comorbidities. Conclusion: This cohort of people with gout and COVID-19 who were hospitalized had high frequencies of ventilatory support and death. This suggests that patients with gout who were hospitalized for COVID-19 may be at risk of poor outcomes, perhaps related to known risk factors for poor outcomes, such as age and presence of comorbidity.
Original languageEnglish
Pages (from-to)948-953
Number of pages6
JournalACR Open Rheumatology
Issue number11
Publication statusPublished - Nov 2022


Dive into the research topics of 'Characteristics and Outcomes of People With Gout Hospitalized Due to COVID-19: Data From the COVID-19 Global Rheumatology Alliance Physician-Reported Registry'. Together they form a unique fingerprint.

Cite this